NASDAQ:TENX

Tenax Therapeutics Q1 2026 Earnings Report

Tenax Therapeutics logo
$13.64 +1.39 (+11.35%)
Closing price 06/23/2026 04:00 PM Eastern
Extended Trading
$13.77 +0.13 (+0.95%)
As of 06:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tenax Therapeutics EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Tenax Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tenax Therapeutics Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

Tenax Therapeutics' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tenax Therapeutics Earnings Headlines

The Treasury just bought its own debt
On April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - while former Treasury Secretary Hank Paulson publicly warned of collapsing demand for U.S. bonds. According to Garrett Goggin, CFA, CMT, with 20 years studying gold and debt cycles, this is the moment miners priced for a world that no longer exists stand to benefit most. As natural bond buyers disappear and the Fed steps in, the move in gold may only be beginning.tc pixel
See More Tenax Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email.

About Tenax Therapeutics

Tenax Therapeutics (NASDAQ:TENX) is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions. The company conducts preclinical and clinical studies under the guidance of U.S. Food and Drug Administration regulations and is advancing its most advanced candidates toward pivotal trials.

Headquartered in Exton, Pennsylvania, Tenax Therapeutics serves hospitals, surgery centers and other healthcare facilities primarily in North America. The company collaborates with academic institutions and strategic partners to advance its pipeline. Tenax is managed by a team of executives with backgrounds in pharmaceutical development and commercialization, and it is publicly traded on the NASDAQ under the ticker symbol TENX.

View Tenax Therapeutics Profile